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Background: Women with type 1 diabetes face particular demands in their lives in relation to childbearing. During
pregnancy, in order to optimize the probability of giving birth to a healthy child, their blood glucose levels need to
be as normal as possible. After childbirth, they experience a ‘double stress’: in addition to the ordinary challenges
they face as new mothers, they also need to focus on getting their blood glucose levels normal. To improve
self-management of diabetes and overall well-being in women with type 1 diabetes, a person-centered web-based
support was designed to be tested in a randomized controlled trial (RCT) to be used during pregnancy and early
motherhood. This protocol outlines the design of this RCT, which will evaluate the effectiveness of the specially
designed web-based support for mothers with type 1 diabetes in Sweden.
Methods/Design: The study is designed as an RCT. The web support consists of three parts: 1) evidence-based
information, 2) a self-care diary, and 3) communication with peers. The primary outcome is general well-being
evaluated with the Well-Being Questionnaire short version (W-BQ12) and diabetes management evaluated with the
Diabetes Empowerment Scale, short version (SWE-DES). Women attending six hospital-based antenatal care centers
in Sweden are invited to participate. The inclusion period is November 2011 to late 2014. The allocation of participants
to web support (intervention group) and to usual care (control group) is equal (1:1). In total, 68 participants in each
group will be needed to reach a statistical power of 80% with significance level 0.05.
Discussion: The web support is expected to strengthen the women’s personal capacity and autonomy during
pregnancy, breastfeeding, and early motherhood, leading to optimal well-being and diabetes management.
Trial registration: ClinicalTrials.gov: NCT01565824 (registration date March 27th 2012).
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Randomized controlled trialBackground
Maternal type 1 diabetes complicates pregnancy, child-
birth and the time just after childbirth. Consequences for
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unless otherwise stated.also perinatal mortality. Maternal concerns include in-
creased likelihood of worsened diabetes-related vascular
complications, pre-eclampsia and eclampsia, and of cae-
sarian section and vacuum extraction/forceps vaginal de-
livery [1,2]. The degree of complications is mainly related
to maternal glycemia, where abnormal blood glucose
levels increase adverse outcomes. Optimized maternal
normoglycemia from pre-conception through pregnancy
is the most important tool available to minimize compli-
cations and increase the likelihood that a woman will give
birth to a healthy child [1,3]. During pregnancy, all womenral. This is an Open Access article distributed under the terms of the Creative
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(up to two or three times more). For women with diabetes
treated with insulin, this means that, in order to optimize
the situation for the coming offspring, they need to parry
the successively increased insulin need through intensive
blood glucose controls and continuous insulin dose in-
creases combined with a structured diet and activity plan
[2-4]. Directly after childbirth the insulin need decreases,
often to less than the pre-gestational levels [5].
Diabetes is unique in that much of the day-to-day
responsibility for care rests with the individuals who
have the disease. Our earlier research in Sweden has
highlighted the vulnerable situation for women with type
1 diabetes in relation to childbearing. During pregnancy,
they struggle day and night to achieve normal blood glu-
cose levels in an attempt to ensure that the fetus/child will
be born healthy; they typically experience frequent hy-
poglycemic episodes and feelings of stress, worry and inse-
curity [6-8]. It has been found that this demanding
situation is worsened if care providers lack competence
and also if the mothers feel left aside by healthcare
workers who give more attention to the unborn child than
to the women themselves. After childbirth, the intensive
health care provided during pregnancy and childbirth is
interrupted, placing the new mothers in a vulnerable si-
tuation as they experience unstable glycemia and more
hypoglycemic episodes in relation to breastfeeding [8].
The mothers also described that they down-prioritized
their own needs in favor of the child’s [9]. Compared to
mothers without diabetes, they were more affected by
daily life disruptions [10] and reported lower levels of
well-being [11].
A structured literature review of 16 identified studies
performed in Sweden, USA, Australia, Greece, Israel,
Italy and the UK [12] has indicated similar results.
Women with type 1 diabetes who were in transition to
motherhood experienced a variety of psychosocial issues:
increased levels of anxiety, diabetes-related distress,
guilt, a sense of disconnectedness from health profes-
sionals, and a focus on the medicalization of pregnancy.
A trusting relationship with health professionals, sharing
experiences with other women with diabetes, active so-
cial support, and shared decision making and responsi-
bilities for diabetes management helped them achieve a
positive transition to motherhood. The authors con-
cluded that health professionals can promote a positive
transition to motherhood by proactively supporting
women with type 1 diabetes in informed decision ma-
king, by facilitating communication with the health-care
team and by coordinating care [12].
Thus existing research shows that the period of preg-
nancy, childbirth and early motherhood is characterized
by an increased risk of complications in both the woman
with type 1 diabetes and the fetus/child, and that thewoman experiences a complex everyday situation and a
lower sense of well-being. There is an obvious need for
extended person-support - from professionals, family
and friends and also peers, that is, mothers with similar
experiences of diabetes and childbearing.
Our own research shows that the use of Internet com-
munication is needed and expected by childbearing
women with type 1 diabetes [13]. Therefore, we suggest
that a person-centered web-based support - one that is
available 24/7 and enables users to document their ex-
periences and share in decision-making related to their
care - as a complement to usual health-care arrange-
ments may strengthen self-management capabilities and
thus well-being in women with type 1 diabetes during
pregnancy, childbirth and early motherhood. To our
knowledge, such a person-centered web-based support
has not yet been evaluated.
Objective
This protocol outlines the design of a specially created
web-based support system for women with type 1 dia-
betes during pregnancy and in early motherhood, tested
in a randomized controlled trial (RCT).
Methods/Design
Study design
The study is labeled MODIAB-Web and is designed as
an RCT to evaluate the effect of a web-based support
system on well-being and diabetes management in the
study group. An equal number of study participants,
pregnant women with type 1 diabetes, will be included
in the intervention group and control group (1:1). Web-
based support will be offered to the intervention group
as a complement to the usual diabetes and pregnancy
care. Women allocated to the control group will receive
the usual care. The study design is in accordance with
the CONSORT recommendation for reporting prag-
matic randomized controlled trials [14]. The flow of the
RCT is illustrated in Figure 1.
Sample size estimation
Sample size estimation in this RCT is based on the two
primary outcome variables: 1) general well-being mea-
sured by the Well-Being Questionnaire (W-BQ12) and 2)
diabetes management measured by the Swedish Diabetes
Empowerment Scale (SWE-DES). In order to detect a
clinically relevant difference of 1.25 in well-being between
the intervention group and the control group, 68 subjects
will be needed in each group to reach a statistical power
of 80%, assuming a SD of 0.40 in each group, with a sig-
nificance level 0.05. Similarly, to detect a difference of 0.2
in diabetes management, 68 subjects will be needed in
each group to reach a statistical power of 80%, assuming a
SD of 2.5 in each group, with a significance level 0.05. A
Figure 1 Flow diagram MODIAB-Web evaluating a web-based support for pregnant women and new mothers with type 1 diabetes
mellitus in Sweden: study protocol for a randomized controlled trial.
Adolfsson et al. Trials 2014, 15:513 Page 3 of 7
http://www.trialsjournal.com/content/15/1/513total sample size of 160 has been chosen to compensate
for a probable 10% loss to follow-up.
Participants and recruitment
A total of 160 participants will be recruited to the MODIAB-
Web study performed in western and central Sweden. The
enrollment started in two centers in November 2011 in the
western region of Sweden. Successively, another four centers
from the central part of Sweden were included; one was
added in June 2012, another one in October 2012 and finally
two more were included in June 2013. All study centers are
hospital based. A list of participating study centers can be
obtained upon request from the corresponding author.
One diabetes midwife in the antenatal care unit at
each hospital-based study center identifies all pregnant
women with type 1 diabetes. If women registered at thestudy units meet the inclusion criteria and do not meet
any exclusion criteria, the midwife provides them with
oral and written information about the study early in
their pregnancy. If a woman agrees to participate in the
study, she signs an informed consent form.
Inclusion criteria
Participants have to fulfill the following criteria to be eligible
for inclusion: literate and Swedish-speaking pregnant women
over 18 years of age with a diagnosis of type 1 diabetes and
registered at one of the six participating study centers, who
have provided written informed consent beforehand.
Exclusion criteria
Eligible participants will be excluded if they meet the
following criterion: miscarriage before randomization,
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trol group in the ongoing study, except randomized
women who miscarry (first trimester) and are pregnant
again during the data collection period; those who mis-
carried earlier but are now pregnant will be connected
to the group to which they were randomized in the earl-
ier pregnancy (intervention or control), and all data will
be collected on this new pregnancy.Withdrawal criteria
Participants are withdrawn from the trial after ran-
domization if they meet the following criteria: miscar-
riage, termination of pregnancy, intrauterine fetus death
during the pregnancy or infant death within six months
after birth.Ethical considerations
The study adheres to the principles of the Declaration
of Helsinki [15] and has been approved by the Ethics
Committee of Gothenburg, Sweden (No. 659-09). Written
consent will be obtained from each participant after she
has received written and verbal information about the
study and before the baseline assessment. All participants
have the right to withdraw from the study at any time.Randomization and allocation concealment
Participants are randomly allocated to the intervention
group (IG) with web support with evidence-based infor-
mation, self-care diary and communication with preg-
nant women with type 1 diabetes in addition to usual
care, or to the control group (CG) provided only the
usual care. Randomization is performed before baseline
assessment.
The randomization is prepared with a unique code
that consists of a first code letter identifying each center,
a second code letter identifying which group it belongs
to, and intervention (IG) or control (CG) followed by a
consecutive number. Baseline questionnaires are marked
with unique code letters/numbers and placed in a closed
envelope. The envelopes are produced in blocks of ten,
five IG and five CG. This is prepared by the research
group and includes the single blind number. The alloca-
tion of participants will be equal (1:1) in blocks of ten
for each of the six centers. After informed consent is re-
ceived, the responsible diabetes midwife at each center
gives the included woman a closed envelope and re-
gisters her personal information and the obtained code
letters/numbers. The key connecting the code with the
woman’s personal information is stored in a safe location
at the study center, in accordance with that specific hos-
pital’s policy. All data files used for data analysis contain
the code number as the only source of identification.Blinding
Due to the nature of this trial it is not possible to blind
the participants. Nevertheless, the diabetes midwives in
charge of the random allocated sequence at the centers
are not involved in the preparation of the envelopes, the
use of web-based support or in the statistical analyses.
Intervention
The web support group - intervention group
All of the women receive the usual care at one of the six
study centers in Sweden. Each center has a special pro-
gram for pregnant women with type 1 diabetes, and
what constitutes usual care varies slightly between the
care centers. However, all women have frequent contact
with a midwife specialized in type 1 diabetes, an obstet-
rician and an endocrinologist during pregnancy and at
one follow-up visit after childbirth.
In order to further support the women’s well-being
and diabetes management, the intervention offers com-
plementary web-based, person-centered support [16-18]
in addition to usual care.
The web support springs from a holistic approach and
consists of three components: 1) evidence-based infor-
mation divided into three parts - being pregnant, labor
and childbirth, and life as a new mother; 2) a self-care
diary for self-reported monitoring of blood glucose, in-
sulin doses, diet, activities and daily mood - measures
can be viewed and evaluated in tables and diagrams to
support decision making and self-care; and 3) a discus-
sion forum for peer support divided into three parts -
being pregnant, labor and childbirth, and life as a new
mother - moderated by the research group. The website
also provides a Frequently Asked Questions section as
well as links to other sites that are relevant for child-
bearing women with type 1 diabetes.
The web-based information for pregnant women and
new mothers with type 1 diabetes has been developed
with a participatory design in seven different stages. The
development process was driven by researchers, but it
also engaged health-care professionals such as nurses,
midwives, and physicians specializing in diabetes care,
pediatrics, obstetrics and breastfeeding [18]. The web
prototype containing the elements of the web support
was further developed and tested by potential users,
pregnant women and mothers with type 1 diabetes [16]
before the web support program was launched.
The web-support system is used freely by the partici-
pants in the intervention group. There is no requirement
regarding time spent logged into the system. If a par-
ticipant in the intervention group has not accessed the
web-based support within the last fortnight, a reminder
is sent out via text message. The research group has no
way of monitoring and/or limiting access to other web-
based forums in relation to diabetes or childbearing
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ent logons to the system is required for the participant
to be considered to be adhering to the intervention.
Control group
The women in the CG receive the same usual care at
one of the six study centers in Sweden (described above)
as those in the IG.
Follow-up period and outcome measurement
During the 18-month follow-up period, the primary and
secondary outcomes are tested at baseline, early pregnancy
(T0), late pregnancy (T1), two months after childbirth
(T2), and six months after childbirth (T3) (see Figure 2).
Outcome measures are collected by questionnaires mailed
to the participants in IG and CG. Participants who have
not returned the questionnaire within ten days receive a
phone call from the study coordinator or project assistant
as a gentle reminder.
The study coordinator takes responsibility for the collec-
tion and entry of data into the correct computer files per
protocol. Data collection will not be continued if a subject
has been excluded from the study or has opted out. All data
entry will be reviewed by two members of the research
group who have not entered any of the data. The primary in-
vestigator (PI) has responsibility for the final data files and
decides who will be granted access and for what purpose.
The PI is also responsible for documenting and communi-
cating any modifications in study protocol to all relevant par-
ties. The sponsors and funders of this trial have no influence
over any part of the study’s design or reporting of outcomes.
Primary outcome measures
The primary outcome of general well-being is evaluated
with the Well-Being Questionnaire, short version (W-BQ12)Figure 2 Time periods for measurement of primary and secondary outc[19] and diabetes empowerment with the Diabetes
Empowerment Scale, short version (SWE-DES) [20].Secondary outcomes measures
Coping in daily life is evaluated using the Sense of Coherence
13-item questionnaire (SOC-13 items) [21], and self-rated
health will be assessed using a single-item EVGFP: excel-
lent, very good, fair or poor. Diabetes management is
measured with the Problem Areas in Diabetes Scale
(SWE-PAID-20) [22]. Fear of hypoglycemia is assessed
with the Hypoglycemia Fear Survey (SWE-HFS) [23].
The breastfeeding rate and experiences of nursing
are evaluated with a specially developed questionnaire.
Medical outcomes in terms of a glycated hemoglobin test
(HbA1c) measured in early and late pregnancy and up to
six months postpartum are collected from electronic
medical records. Usefulness and usability of the web sup-
port are evaluated with a specially developed questionnaire
and the level of participation by using Google Analytics.
Socio-demographic variables, mode of delivery, diabetes
duration and type of insulin administration are also
recorded. All data collection forms listed above can be
obtained from the corresponding author upon request.Validity and reliability of instruments used
The research group has opted to use well-tested instru-
ments as outcome measures whenever possible. All in-
struments have to be available in Swedish to be used in
this study. In the primary outcome measurements the
W-BQ12 has a described Cronbach’s alpha of >0.88 [19]
and its validity is considered to be good. The other pri-
mary outcome scale, SWE-DES, is considered acceptable
in terms of reliability (Cronbach’s alpha range of 0.68 to
0.91 in the 23-question version of the scale) [20,24]. In
terms of secondary outcome, the Sense of Coherenceomes.
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ment that can be applied across different cultures (range
of Cronbach’s alpha 0.70 to 0.92 in 127 studies) [21].
The SWE-PAID-20 questionnaire was reported to have a
(Cronbach’s alpha of 0.94) [25]. The SWE-HFS scale has
also been reported as having good reliability (Cronbach’s
alpha 0.85) and validity [22].
Safety evaluation
The web-based support is not considered to cause any
adverse event. The participants’ pregnancy statuses are
monitored in order to avoid sending questionnaires to
women who have experienced a lost pregnancy, and
dates for delivery are registered to keep the deadlines for
follow-up at two and six months post-partum.
Trial duration
The inclusion period is estimated from November 2011
to December 2014 with follow-up until February 2016.
See Table 1 for a time plan of the study and follow-up.
Statistical analyses plan
The full analysis set, Intention To Treat population (ITT
population), consists of all randomized patients who had
at least one follow-up measurement. The Per-Protocol
population (PP population) consists of all patients in the
ITT population without any significant protocol devia-
tions. The PP population is defined at the clean-file meet-
ing before the database is locked. Primary efficacy analyses
will be performed on our two primary variables general
well-being (W-BQ12) total score and diabetes empower-
ment (SWE-DES) total score, both at six months after de-
livery between the two randomized groups using Fisher’s
non-parametric permutation test on the full analysis set
(ITT population), two-sided test on significance level
0.025. If significant differences in baseline variables are
found between the two randomized groups, a complemen-
tary analysis of covariance (ANCOVA) will be performed
adjusted for these baseline variables. Last observation
carry forward (LOCF) will be applied from two months if
the six months value is missing.
Statistical analyses will be conducted using SPSS, ver-
sion 16.0, and SAS, version 9.2 (Cary, NC). All tests will
be two-tailed and conducted at 5% significance level.Table 1 Time plan of the study and follow-up
Started Will be completed in
Inclusion November 2011 December 2014
Early pregnancy (T0) November 2011 December 2014
Late pregnancy (T1) April 2012 June 2015
Childbirth June 2012 August 2015
2 months post partum (T2) August 2012 October 2015
6 months post partum (T3) November 2012 February 2016Discussion
The unique contribution of this project is the evaluation
of the effectiveness of a specially designed web-based sup-
port for mothers with type 1 diabetes, which is expected
to increase the women’s personal capacity, including
knowledge, and thereby strengthen their autonomy during
pregnancy, breastfeeding and early motherhood.
Web-based support systems have the potential to bridge
gaps that can exist between the different health-care sys-
tems/professionals providing care during the childbearing
period, and especially during early motherhood [13]. They
can also offer increased convenience for users in terms of
time, mobility, and geography, and promote equal access
to quality-assured and evidence-based information [26].
Childbearing women in general are active Internet users
[27,28], and publications show that women with type 1
diabetes seek diabetes-related information online before,
during, and after pregnancy [12,13].
To our knowledge, there is a lack of studies evaluating
web support with a more holistic approach to this group of
women. According to a recent systematic review, there is
limited evidence supporting the use of computer-based self-
management interventions for adults with type 2 diabetes
mellitus [29]. However, this group may not represent the
most experienced Internet users compared to childbearing
women with type 1 diabetes. The reasons for choosing the
Internet as a venue for interventions have to be carefully
considered regarding its contribution to improving people’s
health [26]. From a methodological point of view, the review
by Pal et al. [29] found interventions to be poorly under-
stood and called for more detailed reporting and evaluation
of the design, delivery and effectiveness of computer-based
interventions. The study protocol describing the current
RCT aims to contribute such detailed information about the
study design and the measures undertaken to provide evi-
dence for the use of web-based interventions in a patient
group with specific needs during a vulnerable time of life.
Strength and limitations
The strength of this study is that a generic web-based sup-
port is always accessible, can complement health care in-
dependently of differences in ‘usual care’ provided in each
center, and places no extra burden on healthcare profes-
sionals. However, the use of the web-based support is vol-
untary, which might have an impact on the uptake of the
intervention. We use the CONSORT-EHEALTH Checklist
[29] to report on intervention adherence and measures
undertaken to encourage the use of the web-based sup-
port; for example, an SMS reminder every second week.
One limitation of the study is that it is not feasible to blind
members of the healthcare team to group allocation, a
common problem in clinical trials. Another limitation is
that a higher percentage of women with type 1 diabetes
suffer from miscarriage, which will prolong the data
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to increase the data collection rate.
To conclude, we have described a protocol with a ran-
domized controlled design in order to systematically
evaluate the effectiveness of a web-based support to
women with type 1 diabetes during pregnancy, childbirth
and early motherhood. If proven effective, it will provide
evidence for a modern and accessible complementary
health-care intervention.
Trial status
Status at time of submission of this article: recruiting.
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